Please login to the form below

Not currently logged in
Email:
Password:

Extension for head of Germany’s VFA

Birgit Fischer to remain as chief executive of pharma trade body until 2019          

vfa,
 Birgit FischerGermany's trade body for the pharmaceutical industry the VFA has extended the leadership of its chief executive Birgit Fischer.

Fischer will remain as head of the VFA until 2019 having already served in the role for four years.

She has led the industry voice during an unsettled time for pharma in Germany with many companies critical of the AMNOG system of drug reimbursement introduced in 2010, which has seen several drugs denied market access in the country.

The contract extension is a sign of confidence in Fischer from the VFA, which represents 44 companies from over 100 locations in the country.

Dr Hagen Pfundner, chairman of the board of the VFA said: "We are delighted to be able to continue with Birgit Fischer and her holistic view of the healthcare industry."

Fischer has experience in both the public and private healthcare sector. This includes a spell as CEO of health insurance firm Barmer GEK and as health minister for the North Rhine-Westphalia region of Germany.

Outlining her priorities for the next four years she said: "If we want to use the potential of the research-based pharmaceutical company correctly in healthcare and global competition, Germany needs an industrial and employment model that has innovation at the centre."

 

3rd February 2015

From: Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics